Cover Image
Market Research Report

China Pharmaceuticals & Healthcare Q2 2020

Published by Fitch Solutions, Inc. Product code 209173
Published Content info 86 Pages
Delivery time: 1-2 business days
Back to Top
China Pharmaceuticals & Healthcare Q2 2020
Published: February 25, 2020 Content info: 86 Pages

Key View:

China represents an increasingly attractive investment destination for pharmaceutical firms due to a multitude of

advantages including a rapidly ageing population, well-established manufacturing industry for pharmaceuticals and notable

government commitment to sector development. Crucially, China will continue to expand access to its universal healthcare scheme

through reform and liberalisation of its healthcare sector, improving access for low and middle-income patients. This will significantly

increase the demand for medicines, thus providing an improved outlook for healthcare providers and pharmaceutical firms.

Table of Contents
Product Code: SSCN03_20200401

Table of Contents

  • Key View
  • SWOT
  • Industry Forecast
  • Pharmaceutical Market Forecast
  • Healthcare Market Forecast
  • Prescription Drug Market Forecast
  • Patented Drug Market Forecast
  • Generic Drug Market Forecast
  • OTC Medicine Market Forecast
  • Pharmaceutical Trade Forecast
  • Industry Risk/Reward Index
  • Asia Pacific Innovative Pharmaceuticals Risk/Reward Index
  • Innovative Pharmaceuticals Risk/Reward Index
  • Regulatory Development
  • Regulatory Review
  • Market Overview

Competitive Landscape

  • Company Profile
  • AstraZeneca
  • Bayer HealthCare
  • China Shijiazhuang Pharmaceutical Group (CSPC)
  • Eli Lilly (Lilly China)
  • GlaxoSmithKline
  • MSD
  • Merck KGaA
  • North China Pharmaceutical Corporation
  • Novartis
  • Pfizer
  • Roche
  • Sanofi
  • Shanghai Pharmaceuticals Holding Co
  • Sinopharm
  • China Demographic Outlook
  • Pharmaceuticals & Healthcare Glossary
  • Pharmaceuticals & Healthcare Methodology
Back to Top